medigraphic.com
ISSN 1561-3119 (Electronic)

2019, Number 3

<< Back Next >>

Rev Cubana Pediatr 2019; 91 (3)

Fecal microbiota’s transplant

Castañeda GC

Language: Spanish
References: 56
Page: 1-20
PDF size: 325.08 Kb.


ABSTRACT

Introduction: Fecal microbiota´s transplant (TMF, by its acronym in Spanish) is based on the infusion of fecal material from a healthy subject to another patient due to a specific condition related to intestinal microbiota dysbiosis. Among the indications used with promising results in the last 20 years are the ones used for the infection by Clostridium difficile.
Objective: To analyze the most advanced knowledge and advantages of TMF in different conditions in humans, especially in childhood.
Method: Publications on this condition in Spanish and English in PubMed, Google Scholar, SciELO and Latindex databases from 2015 to January 30, 2019 were reviewed.
Results: Historical background, criteria for indication of TMF, donor’s selection procedure, preparation and preservation of fecal material, administration routes, risks and adverse effects, and results achieved in recent years worldwide are determined. 90 % resolution of symptoms in recurrent infection by Clostridium difficile is described.
Final considerations: The TMF is an effective and safe treatment, easy to perform and of good tolerance, with economic and scientific impact, whose main indication approved by international organizations of the medical community is the recurrent infection or relapse of Clostriium difficile in adults and children. Other indications tested are chronic intestinal inflammatory diseases, especially ulcerative colitis; irritable bowel syndrome, metabolic diseases as obesity and diabetes mellitus type 2, and neuropsychiatric ones that are associated with imbalance of the intestinal microbiota.


REFERENCES

  1. Kim WS, Kim HJ. Is expansion of fecal microbiota transplantation available? Korean J Gastroenterol. 2017;70(4):211-3. Access: 2019/01/04. Available at: https://doi.org/10.4166/ kjg.2017.70.4.211ne

  2. Park JH. Clinical usefulness of fecal microbiota transplantation. J Nerogastroenterol Motil. 2017;23(2):149-50. Access: 2019/01/05. Available at: https://doi.org/10.5056/ jnm.17024

  3. Rossen NG, Mac Donald JR, de Vries EM. Fecal microbiota transplantation as novel therapy in gastroenterology. WJG. 2015;21(17):5359-71. Access: 2019/01/04. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419078/

  4. Hourigan SK, Oliva-Hemker M. Fecal microbiota transplantation in children: a briefreview. Pediatr Res. 2016;80(1):2-6. DOI: 10.1038/pr.2016.48. Epub 2016 Mar 16. Access: 2019/01/05. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26982451

  5. Waye S, Atkins K, Kao D. Costaverted with timely fecal microbiota transplantation in the management to recurrent Clostridium difficile infection in Alberta, Canada. J Clin Gastroenterol. 2016;50:747-53. Access: 2019/01/07. Available at: https://www.ncbi. nlm.nih.gov/pubmed/26890327

  6. Merlo G, Graves N, Brain D, Connelly LB, Economic evaluation of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection in Australia. J Gastroenterol Hepatol. 2016:31:1927-32. Access: 2019/01/09. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27043242

  7. Baro E, Galperine T, Denies F, Lannoy D, Lennis X, Odou P, et al. Cost- effectiveness analysis of five competing strategies for the management of multiple recurrent community-onset Clostridium difficile infection in France. PlosOne. 2017;12:e017o258. Access: 2019/01/08. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5245822/

  8. Kim S, Lee Y, Kim Sh. Safety and effectiveness of fecal microbiota transplantation: a systematic review. J Korean Assoc. 2017;60(9):761-68. Access: 2019/01/12. Available at: https://doi.org/10.5124/jka.2017.60.9.761

  9. Choi HH, Cao YS. Fecal microbiota transplantation: current applications, effectiveness and future perspectives. Clin Endosc. 2016;49(3):257-65. Access: 2019/01/10. Available at: https://doi.org/10.5946/ce.2015.117

  10. Li X, GaoX, Hu D, Xiao Y, Li D, Yu G, et al. Clinical efficacy of microbiome changes following fecal microbiota transplantation in children with recurrent Clostridium difficile infection. Front Microbiol. 2018;9:2622. doi: 10.3389/fmicb.2018.02622. Access: 2019/01/18. Available at: https://www.nbci.nim.nih.gov/pubmed/3045008

  11. Eun JH. Is here a potential role of fecal microbiota transplantation in thetreatment of inflammatory bowel disease? Intest Res. 2017;15(2):145-6. Access:2018/12/12. Available at: https://doi.org/10.5217/ir.2017.15.2.145

  12. Zhang T, Xiang J, Cui B, He Z, Li P, Chen H, et al. Cost- effectiveness analysis of fecal microbiota transplantation for inflammatory boweldisease. Oncontarget. 2017;8:88894-902. Access: 2018/12/10. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29179485

  13. Yodoshi T, Hurt TL. Fecal transplantation to patients with refractory very early onset ulcerative colitis. Pediatr Gastroenterol Hepatol Nutr. 2018;21(4):355-60. Access:2018/12/14. Available at: https://doi.org/10.5223/pghn.2018.21.4.355

  14. Tian H, Ding C, Gong J, Ge X, McFarland LV, Gu L, et al.Treatment of slow transit constipation with fecal microbiota translation: a pilot study. J Clin Gastroenterol. 2016; 50:865-70. Access: 2019/01/09. Available at: https://www.ncbi.nlm.nih.gov/pubmed/ 2675114

  15. Johnsen PH, Hlipusch F, Cavanegh JP, Leihkanger IS, Kolstad C, Valls PC, et al. Fecal microbiota transplantation versus placebo by moderate-to-severe irritable bowel syndrome: a double blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018;3:17-24. Access: 2018/12/12. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29100842

  16. Halkjær SI, Christensen AH, Lo BZS, Browne PD, Günther S, Hansen LH, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67(12):2107-15. doi: 10.1136/gutjnl-2018-316434. Epub 2018 Jul 6. Access:2019/01/04. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29980607

  17. Valenzuela A. Trasplante de microbiota fecal y obesidad. SOCHOB. 2016. Acceso: 2018/12/12. Disponible en: http://www.sochob.cl/web1/trasplante-de-microbiota-fecal-y-obesidad/

  18. Kootte RS, Vrieze A, Holleman F. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabertes mellitus. Diabetes Obes Metabol. 2012;14:112-120. Access: 2018/12/10. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21812894

  19. Vrieze A, van Noood E, Holleman F. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals withmetabolic syndromes. Gastroenteology. 2013;2143:913-6. Access: 2018/12/06. Available at: https://www.ncbi.nlm.nih.gov/ pubmed/22728514

  20. He Z, Cui BT, Zhang T, Li P, Long CY Ji, GH Z. Fecal microbiota transplantation cured epilepsy in a case with Crohn's disese: the first report. World J Gastroenterol. 2017;23: 3565-8. Access: 2019/01/12. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/ PMC5442093/

  21. Kang DK, Adams JB, Gregory AC, Borody T, Chittick L, Fasano, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017;5:10. doi:10.1186/s40168-016-0225_7. Access: 2018/12/06. Available at: https://microbiomejournal.biomedcentral.com/articles/10.1186/ s40168-016-0225-7

  22. Kao D, Roach B, Park H, Hotle N, Madsen K, Bain V, et al. Fecal microbiota transplantation in the management of hepatic encephalopathy. Hepatology. 2016;63:339-40. Access: 2019/01/10. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26264779

  23. Espinoza R, Quera R, Meyer L, Rivera D. Trasplante de microbiota fecal. Primer caso reportado en Chile y revisión de la literatura. Rev Chilena infectol. 2014;31(4):477-82. Acceso: 06/01/2019. Disponible en: https://scielo.conicyt.cl/pdf/rci/v31n4/art16.pdf

  24. Villatoro-Villar M, Minero JI, Rubio-Covarrubias E. Experiencia en trasplante de microbiota fecal en el Hospital Central Militar. Rev Sanid Milit Mex. 2015;69(35):417-26. Acceso: 06/01/2019. Disponible en: http://www.medigraphic.com/cgibin/new/resumen.cgi? IDARTICULO=60849

  25. Waldbaum C, Antelo P, Sordá J. Infección severa y complicada por Clostridium difficile resuelta con trasplante de microbiota. Acta Gastroenterol Latinoam. 2017;47(3):211-5. Acceso: 05/01/2018. Disponible en: http://www.medigraphic.com/cgibin/new/resumen.cgi? IDARTICULO=60849; https://www.redalyc.org/pdf/1993/199352918009.pdf

  26. Zamudio VP, Ramirez-Mayans JA, Toro EM, Cervantes R, Zárate F, Montjo E, et al. Importancia de la microbiota gastrointestinal en pediatría. Acta Pediatr Mex. 2017;38(1):49-62. Acceso: 14/12/2018. Disponible en: http://www.medigraphic.com/pdfs/actpedmex/ apm2017/apm171f

  27. Castañeda C. Microbiota intestinal y salud infantil. Rev Cubana Pediatr. 2017;90(1). Acceso: 11/12/2018. Disponible en: http://www.revpediatria.sld.cu/%20index.php/%20 ped/article/w/320.

  28. Rodríguez de Santiago E, García A, Ferre C, Aguilera L, López A. Trasplante de microbiota fecal: Indicaciones, metodología y perspectivas futuras. Rev Argent Coloproct. 2015;26(4):225-34. Acceso: 10/12/2018. Disponible en: http://www.sacp.org.ar/revista/21-numeros-anteriores/volumen-26-numero-4/145-enrique-rodriguez-de-santiago

  29. Drew I. Microbiota: Resseiding the gut. Nature. 2016;540:S109-S112. doi:10.1038/5405.109ª. Access: 2018/12/06. Available at: https://www.ncbi.nlm.nih.gov/ pubmed/28002392

  30. Hu J, Chen L, Tang Y, Xie C, XuB. Standardized preparation for fecal microbiota transplantation in pigs. Front Microbiol. 2018 Jun;9:a1328. doi: 10.3339/fmiccb.2018.01328. Access: 2019/12/05. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29971061

  31. Eiseman B, Silen W, Bascom GS, Karvar AI. Fecal enema as an adjunct in thetreatment of pseudo membranous enterocolitis. Surgery. 1958;44:854-9.

  32. Widlak M, Bhala N, Moore D, Price M, Sharma N, Iqbal TH. Systematic review with meta-analysis: the efficacy of faecal microbiot transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017;46(5):479-93. doi:10.1111/apt.14201. Epub 2017 Jul 14.

  33. Quraishi MN, Widlak M, Hala N, Moore D, Price M, Sharma N, et al. Systematic review with meta-analysis: theef ficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017;46(5):479-93. doi: 10.1111/apt.14201.

  34. Thiang XY, Wang YZ, Li XL, Hu H, Lu HF, Li D, et al. Safety of fecal microbiota through in Chinese chldren: a single-center retrospective stydy. World J Clin cases. 2018;6(16):1121-7. doi: 10.12998/wjcc.v6i16.1121

  35. Wang AY, Popov J, Pai N. Fecal microbial transplant for the treatment of pediatric inflammatory bowel disease. World J Gastroenterol. 2016;22(47):10304-15. doi: 10.3748/org.v22i47.10304. Access: 2018/12/12. Available at: https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC5175243/

  36. Vyas D, Aekka A, Vyas A. Fecal transplant policy and legislation. World J Gastroenterol. 2015;21(1):7-11. doi: 10.3748/wjgv21.i1.6. Access: 2018/12/02. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25574076

  37. Verelle F, JanssensY, Wynendaee E, Spiegeleer BD. Fecal microbiota transplantation. A regulatory hurdle? BMC Gastroenterol. 2017;17:128. doi: 10.1186/s12876-017-0687-5.8.38.

  38. Davidovics ZH, Vance K, Etienne N, Hyams JS. Fecal transplantation successfully treats recurrent D-Lactic Acidosis in a child with short bowel syndrome. JPEN J Parenterer Enteral Nutr. 2017;41(5):896-97. doi10.1177/0148607115619931.

  39. Surawicz CM, Brandt IJ, Binion DG. Guidelines for diagnostic, treatment and prevention of Clostridium difficile infections. Amer J Gastroenterol. 2013;108(4);478-90. doi: 10.1038/ajg.2013.4. Epub 2013 Feb 26. Access: 2018/12/08. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23439232

  40. García A, Rodríguez de Santiago E, Aguilera L, Ferre C, López. Trasplante de microbiota fecal. Gastroenterol Hepatol. 2015;38(3):123-34.

  41. Gupta S, Allen-Vercoe E, Petrof EC. Fecal microbota transplantation: in perspective. Therap Adv Gastroenterol. 2016;(2):229-39. doi: 10.1177/1756283X15607414. Access: 2018/12/02. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4749851/20

  42. Kelly CR, Kahn S, Kashyap P, Laine L, Rubin D, Atreja A, et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology. 2015;149:223-37. doi: 10.1053/j.gastro.2015.05.008. Access: 2018/12/08. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25982290

  43. Nicholson M, Alexander E, Bardett M. Microbiota transplantation in pediatric Clostridum difficile infection, a multicenter study [abstract 481]. North Amer Society Pediatric Gastroenterology, Hepatology and Nutrition. Annual Meeting. November 1-4, 2017. Las Vegas, NY: Meeting; 2017.

  44. Kahn SA, Young S. Colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection in child. Amer J Gastroenterol. 2012;107:1930-1. doi: 10.1038/ajg.2012.351. Access: 2018/12/10. Available at: https://www.ncbi.nlm.nih.gov/ pubmed/23211865

  45. Davidovics ZH, Michail S, Nicholson MR, Kociolek LK, Pai N, Hansern R, et al. FMT Special Interest Groupof North American Society for PediatricGastroenterology, Hepatology, Nutrition, the European Society for Pediatric Gastroenterology Hepatology, Nutrition. JPGN. 2019:68(1).130-43. doi: 10.1097/MPG.0000000000002205. Access: 2019/01/07. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30540704

  46. Drekonje D, Reich J, Gezahege S, Green N, Shauket A, MacFarland R, et al. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann Intern Med. 2015;162(9):630-8.

  47. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franson MA, et al. Trending Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2011;9(12):1044-8. doi: 10.1016/j.cgh.2011.08.014. Epub 2011 Aug 24. Access: 2019/01/05. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21871249

  48. Moyedi P, Surete MG, Kim PE. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomised controlled trial. Gastroenterology. 2015;149(1):102-9. doi: https://www.ncbi.nlm.nih.gov/pubmed/2187124910.1053/j.gastro. 2015.04.001. Epub 2015 Apr 7. Access: 2018/12/010. Available at: https://www.ncbi. nlm.nih.gov/pubmed/25857665

  49. Rosen NG, Fuentes S, van de Spek MJ. Findings from randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterologyy. 2015;149(1):110-118c114. doi: 10.1053/j.gastro.2015.03.045. Epub 2015 Mar 30. Access: 2018/12/10. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25836986

  50. Mintz M, Khair S, Grewal S, LaComb JF, Park J, Channer B, et al. Longitudinal microbio metanalysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/orulcerative colitis. 2018:13(1):e0190997. doi: 10.1371/journal.pone.0190997. eCollection 2018. Access: 2018/12/12. Available at: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0190997

  51. Zhang F, Cui B, He X, Nie Y, Wu K, Fan D. FMT-standarization Study Group. Protein Cell. 2018;9(5):462-73. Access: 2019/01/06. Available at: https://doi.org/10.1007/s13238-018-0541-8

  52. Nuñez ME, Cebada M, Contreras B. Trasplante de microbiota fecal: protocolo de estandarización para la selección de donadores. An Méd. 2017;63(2):114-9. Acceso: 05/01/2019. Disponible en: http://www.medigraphic.com/pdfs/abc/bc-2017/bc172g.pdf

  53. Youngster I, Mahabamunuge J, Systrom HK, Sauk J, Khalili H, Levin J, et al. Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection. BMC Med. 2016;14(1):134. doi:10.1186/s12916-016-0680-9. Access: 2018/12/14. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27609178

  54. Jiang ZD, Alexander A, Ke S, Valilis EM, Hu S, Li B, et al. Stability and efficacy of frozen and lyophilized fecal microbiota transplant (FMT) product in a mouse model of Clostridium difficile infection (CDI). Anaerobe. 2017;48:110-14. doi: 10.1016/j.anaerobe.2017.08.003. Epub 2017. Aug 9. Access: 2018/12/09. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28801119

  55. Baxter M, Colville A. Adverse events in fecal microbiota transplant: a review of the literature. J Hosp Infect. 2016;92(2):117-27. doi:10.1016/jhin2015.10024. Epub 2015. Dec 15. Access: 2018/12/12. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26803556

  56. Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV, Knight R. Current understanding of the human microbiome. Nature. 2018;24:392-00. Access: 2018/12/05. Available at: https://www.nature.com/articles/nm.4517




2020     |     www.medigraphic.com